US drugmaker Pfizer said on Wednesday it was recalling Oxbryta, a treatment for sickle-cell anaemia, from all markets where it is approved, citing risks of painful complications and fatalities. Pfizer acquired Oxbryta, also known as voxelotor, as part of its $5.4 billion buyout of Global Blood Therapeutics in 2022.